Imbruvica and Keytruda drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imbruvica (ibrutinib) and Keytruda (pembrolizumab). Common drug interactions include arthralgia among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Imbruvica and Keytruda. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

On Jul, 07, 2026

31 people who take Imbruvica and Keytruda together, and have interactions are studied.

Imbruvica and Keytruda drug interactions.

What are the common drug interactions of Imbruvica and Keytruda, by gender? *:

female:

Arthralgia (joint pain)
Malignant melanoma (skin cancer rises from melancytes)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Infection
Myalgia (muscle pain)
Nasopharyngitis (inflammation of the nasopharynx)
Pain
Renal impairment (severely reduced kidney function)
White blood cell count decreased
Impaired healing

male:

Pneumonia
Bone pain
Fall
Hypotension (abnormally low blood pressure)
Peripheral swelling
Pulmonary oedema (fluid accumulation in the lungs)
Decreased appetite
Contusion (a type of hematoma of tissue in which capillaries)
Asthenia (weakness)
Gallbladder obstruction

What are the common drug interactions of Imbruvica and Keytruda, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Pneumonia
Bone pain
Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Neutropenia (an abnormally low number of neutrophils)
Pyrexia (fever)
Respiratory failure (inadequate gas exchange by the respiratory system)
Septic shock (shock due to blood infection)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Death

60+:

Fall
Hypotension (abnormally low blood pressure)
Contusion (a type of hematoma of tissue in which capillaries)
Dry mouth
Dry skin
Onychoclasis (breaking of the nails)
Rash macular (small, flat red spots)
Stomatitis (inflammation of mucous membrane of mouth)
Urinary tract infection
Decreased appetite

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 23 people, 74.19%
High Blood Pressure: 7 people, 22.58%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 6 people, 19.35%
Stress And Anxiety: 6 people, 19.35%
High Blood Cholesterol: 6 people, 19.35%
Gastric Ph Decreased: 6 people, 19.35%
Hypokalemia (low potassium): 5 people, 16.13%
Neoplasm Malignant (cancer tumour): 4 people, 12.90%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 12.90%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 4 people, 12.90%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and Keytruda?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously